National Institute of Neurological Disorders and Stroke (NINDS) clinical trial pipeline

7 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 1 with a minor change only.

1. Notable

   Epilepsy: Screening and Evaluation

   Primary and study completion pushed from Jul 30, 2027 to Jul 31, 2037

   National Institute of Neurological Disorders and Stroke (NINDS)·Not specified·Unusual date· NCT03478852· Registry history of NCT03478852 on ClinicalTrials.gov (opens the registry)

   Updated Oct 7, 2026

2. Notable

   Influence of Brain Oscillation-Dependent TMS on Motor Function

   Primary and study completion pushed from Mar 31, 2029 to Mar 30, 2030

   National Institute of Neurological Disorders and Stroke (NINDS)·Not specified· NCT03288220· Registry history of NCT03288220 on ClinicalTrials.gov (opens the registry)

   Updated Sep 22, 2026

3. Notable

   Beneficial Effects of Naps on Motor Learning

   Primary and study completion pushed from Aug 1, 2027 to Mar 30, 2030

   National Institute of Neurological Disorders and Stroke (NINDS)·Not specified· NCT04312126· Registry history of NCT04312126 on ClinicalTrials.gov (opens the registry)

   Updated Sep 22, 2026

4. Notable

   Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants…Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

   Primary completion pushed from Sep 1, 2026 to Sep 1, 2027

   National Institute of Neurological Disorders and Stroke (NINDS)·Not specified· NCT06577467· Registry history of NCT06577467 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

5. Notable

   Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic…Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

   Enrollment reopened

   National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1· NCT07204977· Registry history of NCT07204977 on ClinicalTrials.gov (opens the registry)

   Updated Oct 1, 2026

6. Notable

   Periganglionic Resiniferatoxin · Intractable Pain Due to…Periganglionic Resiniferatoxin · Intractable Pain Due to Cancer-induced Bone Pain

   Start date pushed from Aug 27, 2026 to Nov 27, 2026

   National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1/2· NCT02522611· Registry history of NCT02522611 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.